The FDA has accepted the NDA for ulixacaltamide HCl, a selective T-type calcium channel inhibitor for essential tremor, following positive phase 3 Essential3 trial results.
FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 ...
Involuntary movements like a tremor can feel embarrassing or trigger anxiety, and many people choose to hide them out of fear of how others might perceive them – an experience Canadian-American actor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results